Logo image of MED.DE

MEDICLIN AG (MED.DE) Stock Fundamental Analysis

FRA:MED - Deutsche Boerse Ag - DE0006595101 - Common Stock - Currency: EUR

3  +0.1 (+3.45%)

Fundamental Rating

3

Taking everything into account, MED scores 3 out of 10 in our fundamental rating. MED was compared to 25 industry peers in the Health Care Providers & Services industry. MED has a bad profitability rating. Also its financial health evaluation is rather negative. MED has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year MED has reported negative net income.
In the past year MED had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MED reported negative net income in multiple years.
MED had a positive operating cash flow in each of the past 5 years.
MED.DE Yearly Net Income VS EBIT VS OCF VS FCFMED.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M 80M 100M

1.2 Ratios

The Return On Assets of MED (-1.23%) is worse than 87.50% of its industry peers.
Looking at the Return On Equity, with a value of -5.26%, MED is doing worse than 87.50% of the companies in the same industry.
With a Return On Invested Capital value of 1.74%, MED is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
The Average Return On Invested Capital over the past 3 years for MED is below the industry average of 5.68%.
The last Return On Invested Capital (1.74%) for MED is above the 3 year average (1.64%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -1.23%
ROE -5.26%
ROIC 1.74%
ROA(3y)-0.01%
ROA(5y)0.01%
ROE(3y)-0.06%
ROE(5y)-0.04%
ROIC(3y)1.64%
ROIC(5y)1.41%
MED.DE Yearly ROA, ROE, ROICMED.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 -5

1.3 Margins

With a Operating Margin value of 2.31%, MED is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
In the last couple of years the Operating Margin of MED has remained more or less at the same level.
With an excellent Gross Margin value of 83.19%, MED belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
In the last couple of years the Gross Margin of MED has remained more or less at the same level.
Industry RankSector Rank
OM 2.31%
PM (TTM) N/A
GM 83.19%
OM growth 3Y377.24%
OM growth 5Y1.2%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y0.08%
MED.DE Yearly Profit, Operating, Gross MarginsMED.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

MED has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for MED remains at a similar level compared to 1 year ago.
MED has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for MED has been reduced compared to a year ago.
MED.DE Yearly Shares OutstandingMED.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
MED.DE Yearly Total Debt VS Total AssetsMED.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

MED has an Altman-Z score of 1.48. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MED (1.48) is comparable to the rest of the industry.
MED has a debt to FCF ratio of 10.45. This is a negative value and a sign of low solvency as MED would need 10.45 years to pay back of all of its debts.
The Debt to FCF ratio of MED (10.45) is worse than 66.67% of its industry peers.
MED has a Debt/Equity ratio of 2.00. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.00, MED is doing worse than 66.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2
Debt/FCF 10.45
Altman-Z 1.48
ROIC/WACC0.44
WACC3.96%
MED.DE Yearly LT Debt VS Equity VS FCFMED.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

MED has a Current Ratio of 1.74. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of MED (1.74) is better than 83.33% of its industry peers.
MED has a Quick Ratio of 1.70. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.70, MED belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.7
MED.DE Yearly Current Assets VS Current LiabilitesMED.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

MED shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -154.77%.
The Revenue has been growing slightly by 2.04% in the past year.
The Revenue has been growing slightly by 3.20% on average over the past years.
EPS 1Y (TTM)-154.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.14%
Revenue 1Y (TTM)2.04%
Revenue growth 3Y4.55%
Revenue growth 5Y3.2%
Sales Q2Q%0.96%

3.2 Future

Based on estimates for the next years, MED will show a very strong growth in Earnings Per Share. The EPS will grow by 77.58% on average per year.
MED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.77% yearly.
EPS Next Y352%
EPS Next 2Y126.27%
EPS Next 3Y77.58%
EPS Next 5YN/A
Revenue Next Year0.09%
Revenue Next 2Y1.54%
Revenue Next 3Y1.77%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MED.DE Yearly Revenue VS EstimatesMED.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M
MED.DE Yearly EPS VS EstimatesMED.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 0.4

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MED. In the last year negative earnings were reported.
MED is valuated cheaply with a Price/Forward Earnings ratio of 7.62.
MED's Price/Forward Earnings ratio is rather cheap when compared to the industry. MED is cheaper than 91.67% of the companies in the same industry.
MED is valuated cheaply when we compare the Price/Forward Earnings ratio to 92.74, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 7.62
MED.DE Price Earnings VS Forward Price EarningsMED.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, MED is valued cheaper than 87.50% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MED is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 3.12
EV/EBITDA 3.56
MED.DE Per share dataMED.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MED's earnings are expected to grow with 77.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y126.27%
EPS Next 3Y77.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MED!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDICLIN AG

FRA:MED (2/3/2025, 7:00:00 PM)

3

+0.1 (+3.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04 2024-11-04
Earnings (Next)N/A N/A
Inst Owners2.31%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap142.50M
Analysts83.33
Price Target4.36 (45.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)14.55%
EPS NY rev (3m)14.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.5%
Revenue NY rev (3m)0.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.62
P/S 0.18
P/FCF 3.12
P/OCF 1.61
P/B 0.67
P/tB 0.75
EV/EBITDA 3.56
EPS(TTM)-0.23
EYN/A
EPS(NY)0.39
Fwd EY13.13%
FCF(TTM)0.96
FCFY32.04%
OCF(TTM)1.86
OCFY62.13%
SpS16.23
BVpS4.47
TBVpS4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.23%
ROE -5.26%
ROCE 2.47%
ROIC 1.74%
ROICexc 2.38%
ROICexgc 2.48%
OM 2.31%
PM (TTM) N/A
GM 83.19%
FCFM 5.92%
ROA(3y)-0.01%
ROA(5y)0.01%
ROE(3y)-0.06%
ROE(5y)-0.04%
ROIC(3y)1.64%
ROIC(5y)1.41%
ROICexc(3y)2.1%
ROICexc(5y)1.71%
ROICexgc(3y)2.27%
ROICexgc(5y)1.85%
ROCE(3y)2.33%
ROCE(5y)2%
ROICexcg growth 3Y411.72%
ROICexcg growth 5Y-8.69%
ROICexc growth 3Y421.42%
ROICexc growth 5Y-5.86%
OM growth 3Y377.24%
OM growth 5Y1.2%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y0.08%
F-Score6
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 2
Debt/FCF 10.45
Debt/EBITDA 4.16
Cap/Depr 50.86%
Cap/Sales 5.56%
Interest Coverage 0.78
Cash Conversion 86.71%
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 1.7
Altman-Z 1.48
F-Score6
WACC3.96%
ROIC/WACC0.44
Cap/Depr(3y)34.41%
Cap/Depr(5y)39.93%
Cap/Sales(3y)3.66%
Cap/Sales(5y)4.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-154.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.14%
EPS Next Y352%
EPS Next 2Y126.27%
EPS Next 3Y77.58%
EPS Next 5YN/A
Revenue 1Y (TTM)2.04%
Revenue growth 3Y4.55%
Revenue growth 5Y3.2%
Sales Q2Q%0.96%
Revenue Next Year0.09%
Revenue Next 2Y1.54%
Revenue Next 3Y1.77%
Revenue Next 5YN/A
EBIT growth 1Y-54.13%
EBIT growth 3Y398.94%
EBIT growth 5Y4.45%
EBIT Next Year591.97%
EBIT Next 3Y95.67%
EBIT Next 5YN/A
FCF growth 1Y29.19%
FCF growth 3Y-24.12%
FCF growth 5YN/A
OCF growth 1Y54.52%
OCF growth 3Y-12.96%
OCF growth 5Y22.78%